Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-'408 TE ...
Detailed price information for Aeon Biopharma Inc (AEON-A) from The Globe and Mail including charting and trades.
Discover how Web3 and blockchain are reshaping the construction industry by enhancing project transparency, improving trust, ...
Wrexham Council’s flagship arts and market venue, Ty Pawb, was once again hailed as a “jewel in the crown” during a scrutiny ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback